Uptake and excresion of terbutalin in healthy trained males

Pharmacological properties of in haled and oral terbutalin administrated in healthy trained males

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-002140-40-DK

Enrollment

Unknown

Registered

2014-08-26

Start date

2016-09-17

Completion date

Unknown

Last updated

2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pharmacological properties of terbutalin regarding uptake and excretion MedDRA version: 18.0 Level: SOC Classification code 10022891 Term: Investigations System Organ Class: 10022891 - Investigations

Interventions

Trade Name: Bricanyl Turbohaler Product Name: Bricanyl Turbuhaler Pharmaceutical Form: Inhalation powder INN or Proposed INN: TERBUTALINE SULFATE CAS Number: 23031-32-5 Concentration unit: mg milligra

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Male between 18-40 Physically active at least 5 hours a week Non smoker No daily use of medicine VO2 max at least 60,0 ml/kg/min Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 12 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Hypersensitivity towards the active substance or any one of the other substances within the medicine Coronary heart diease, asthma or other cronical disease Not able to get doctors permission to participate in the trials after an objective test

Design outcomes

Primary

Measure	Time frame
Main Objective: Determine the pharmacological properties of inhaled and oral terbutalin in healthy trained males;Secondary Objective: Not applicable;Primary end point(s): Urine concentratio of terbutalin;Timepoint(s) of evaluation of this end point: The end point will be evalueated in spring of 2016	—

Secondary

Measure	Time frame
Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable	—

Countries

Denmark

Contacts

Public ContactMorten Hostrup Nielsen

Bispebjerg University Hospital

mortenhostrup@gmail.com

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026